company background image
506820 logo

AstraZeneca Pharma India BSE:506820 Stock Report

Last Price

₹6.43k

Market Cap

₹160.6b

7D

-0.8%

1Y

15.4%

Updated

25 Dec, 2024

Data

Company Financials

AstraZeneca Pharma India Limited

BSE:506820 Stock Report

Market Cap: ₹160.6b

506820 Stock Overview

A biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. More details

506820 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance1/6
Financial Health6/6
Dividends2/6

Risk Analysis

High level of non-cash earnings

Dividend of 0.37% is not well covered by free cash flows

Profit margins (5.5%) are lower than last year (13.4%)


My Notes

Capture your thoughts, links and company narrative

AstraZeneca Pharma India Limited Competitors

Neuland Laboratories

BSE:524558

₹177.7b

Eris Lifesciences

NSEI:ERIS

₹182.7b

Caplin Point Laboratories

BSE:524742

₹182.3b

Marksans Pharma

NSEI:MARKSANS

₹133.1b

Price History & Performance

Summary of share price highs, lows and changes for AstraZeneca Pharma India
Historical stock prices
Current Share Price₹6,425.70
52 Week High₹8,139.85
52 Week Low₹4,050.15
Beta0.34
1 Month Change-0.46%
3 Month Change-12.52%
1 Year Change15.38%
3 Year Change112.88%
5 Year Change145.35%
Change since IPO10,978.79%

Recent News & Updates

Recent updates

Shareholder Returns

506820IN PharmaceuticalsIN Market
7D-0.8%1.3%-3.2%
1Y15.4%39.0%18.7%

Return vs Industry: 506820 underperformed the Indian Pharmaceuticals industry which returned 39% over the past year.

Return vs Market: 506820 underperformed the Indian Market which returned 18.7% over the past year.

Price Volatility

Is 506820's price volatile compared to industry and market?
506820 volatility
506820 Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.2%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market4.1%

Stable Share Price: 506820 has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: 506820's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1979800Sanjeev Panchalwww.astrazeneca.in

AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes and immunology diseases.

AstraZeneca Pharma India Limited Fundamentals Summary

How do AstraZeneca Pharma India's earnings and revenue compare to its market cap?
506820 fundamental statistics
Market cap₹160.64b
Earnings (TTM)₹819.20m
Revenue (TTM)₹14.85b

196.1x

P/E Ratio

10.8x

P/S Ratio

Is 506820 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
506820 income statement (TTM)
Revenue₹14.85b
Cost of Revenue₹8.24b
Gross Profit₹6.60b
Other Expenses₹5.78b
Earnings₹819.20m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)32.77
Gross Margin44.46%
Net Profit Margin5.52%
Debt/Equity Ratio0%

How did 506820 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

37%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 23:33
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AstraZeneca Pharma India Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kameswari V. S. ChavaliFirstCall Research